Inactive Instrument

BBI Life Sciences Corporation

Equities

1035

KYG1089Y1180

Biotechnology & Medical Research

BBI Life Sciences Corporation Announces Change of Principal Place of Business in Hong Kong

May 31, 2018 at 04:31 am EDT

The board of directors of BBI Life Sciences Corporation announced that the principal place of business of the Company in Hong Kong has been changed 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong with effect from 31 May 2018.

Latest news about BBI Life Sciences Corporation

LJ Future Ltd completed the acquisition of 43.3% stake in BBI Life Sciences Corporation.	20-06-03	CI
BBI Life Sciences Corporation Appoints Liu Bin as a Non-Executive Director, Effective April 18, 2020	20-04-17	CI
BBI Life Sciences Corporation Did Not Recommend the Payment of A Final Dividend for the Year Ended December 31, 2019	20-03-31	CI
Bbi Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-31	CI
LJ Future Ltd made a proposal to acquire 43.3% stake in BBI Life Sciences Corporation for approximately HKD 850 million.	20-01-19	CI
Bbi Life Sciences Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-27	CI
BBI Life Sciences Corporation Recommends Final Dividend for the Year Ended December 31, 2018, Payable on 31 July 2019	19-03-27	CI
Bbi Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-27	CI
BBI Life Sciences Corporation Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	18-08-30	CI
BBI Life Sciences Corporation Provides Group Profit Guidance for the Six Months Ended June 30, 2018	18-08-14	CI
BBI Life Sciences Corporation Approves Final Dividend for the Year Ended 31 December 2017, Payable on or Around 31 July 2018	18-06-29	CI
BBI Life Sciences Corporation Announces Change of Principal Place of Business in Hong Kong	18-05-31	CI
BBI Life Sciences Corporation Announces Board Changes	18-04-20	CI
BBI Life Sciences Corporation Recommends Final Dividend for the Year Ended 31 December 2017, Payable on 31 July 2018	18-03-26	CI
BBI Life Sciences Corporation Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2017	18-03-26	CI
BBI Life Sciences Corporation Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	17-08-15	CI
BBI Life Sciences Corporation Proposes Final Dividend for the Year Ended December 31, 2016, Payable on June 30, 2017	17-04-24	CI
BBI Life Sciences Corporation Reports Audited Consolidated Capital Expenditure Results for the Year Ended December 31, 2016	17-04-24	CI
BBI Life Sciences Corporation Recommends Final Dividend for the Year Ended December 31, 2016, Payable on June 30, 2017	17-03-24	CI
BBI Life Sciences Corporation Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2016	17-03-24	CI
BBI Life Sciences Corporation acquired Bionics Co., Ltd. for $2.4 million.	16-10-24	CI
BBI Life Sciences Corporation Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016	16-08-30	CI
BBI Life Sciences Corporation Recommends Final Dividend for the Year Ended December 31, 2015, Payable on July 30, 2016	16-04-26	CI
BBI Life Sciences Corporation Recommends Final Dividend for the Year Ended 31 December 2015, Payable on 30 July 2016	16-03-29	CI
BBI Life Sciences Corporation Reports Consolidated Earnings Results for the Year Ended December 31, 2015	16-03-29	CI

Chart BBI Life Sciences Corporation

Duration

Period

More charts

Company Profile

BBI Life Sciences Corporation is an investment holding company principally engaged in the development, manufacture and sales of various life science products used in scientific research, and the provision of life science related services. These products and services offered by the Company is used in the studies of life sciences including animal and plant, disease, medical diagnosis, drug development, food and agriculture industry. The Company has four business segments: deoxyribonucleic acid (DNA) synthesis products, genetic engineering services, life science research consumables as well as protein and antibody related products and services. The principal markets of the Company include the People's Republic of China (the PRC), North America, South America, Europe and Africa.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+45.89%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research